We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sponsors wishing to test new high-risk drugs for the first time in human subjects are advised to conduct additional preliminary studies in some circumstances under a new draft guideline from the European Medicines Agency (EMEA).
Taiwan's Development Center for Biotechnology has signed a nonexclusive research licensing deal with DSM Biologics, a unit of DSM Pharmaceutical Products, and Crucell, the companies announced.
BioLineRx, an Israel-based drug-development company, announced it has signed license agreements to develop and commercialize two new therapeutic candidates.
Canadian drugs sold to consumers in the U.S. via the internet last year were half what they were the year before, according to IMS Health researchers who blamed a variety of market factors for the dramatic plunge in sales volume.
Germany and Italy have decided to recommend human papillomavirus (HPV) vaccination of girls and young women to prevent cervical cancer, Sanofi Pasteur MSD has announced.
Last week's reversal of a district court ruling that blocked a challenge to a key Norvasc patent has triggered an early generic launch of the drug by Mylan Laboratories.
MerLion Pharmaceuticals, a drug-discovery and development company based in Singapore, and Merck Banyu, a wholly owned Japanese subsidiary of Merck, have signed a two-year discovery and licensing agreement.